Table 2. . Baseline disease characteristics in Phase III Studies SC1401 and SC1402.
| Baseline disease characteristics | Placebo (n = 485) | Sareycycline (n = 483) | Placebo (n = 515) | Sareycycline (n = 519) |
|---|---|---|---|---|
| Mean facial inflammatory lesions (n) | 30.2 | 29.7 | 30.2 | 30.3 |
| Facial IGA, n (%): | ||||
| – 3 (moderate) | 410 (84.5) | 413 (85.5) | 439 (85.2) | 440 (84.8) |
| – 4 (severe) | 75 (15.5) | 70 (14.5) | 76 (14.8) | 79 (15.2) |
| Mean IGA for chest | 1.2 | 1.2 | 1.4 | 1.4 |
| Mean IGA for back | 1.6 | 1.6 | 1.8 | 1.8 |
| Baseline IGA ≥2 chest, n (%) | 188 (39) | 190 (39) | 246 (48) | 247 (48) |
| Baseline IGA ≥2 back, n (%) | 261 (54) | 271 (56) | 317 (62) | 325 (63) |
IGA: Investigator's global assessment.